In this issue

Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was shown to attenuate cardiovascular and renal morbidity in patients with type 2 diabetes in the EMPA-REG Outcome trial. EMPA decreased the risk of incident or worsening nephropathy, progression to macroalbuminuria, and the combined endpoint of doubling of serum creatinine and need for renal replacement therapy. This is due, in part, to a reduction in glomerular hypertension. Mayer and colleagues wondered whether EMPA was still effective in patients taking commonly used background medications that also affect glomerular hemodynamics.
Source: Kidney International - Category: Urology & Nephrology Tags: In This Issue Source Type: research